Stockscreener 앱 받기
121.93
1.82%
2.18
시간 외 거래:
121.56
-0.37
-0.30%
Merck Co Inc 주식(MRK)의 최신 뉴스
3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Cut to "Buy" at Wall Street Zen - MarketBeat
Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface - TechStock²
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck & Co., Inc. $MRK Shares Bought by Canada Post Corp Registered Pension Plan - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Garland Capital Management Inc. - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Prime Capital Investment Advisors LLC - MarketBeat
Insider Sell Alert: Johannes Oosthuizen Sells 15,000 Shares of M - GuruFocus
Merck & Co., Inc. (NYSE:MRK) EVP David Michael Williams Sells 5,000 Shares - MarketBeat
Johannes Jacobus Oosthuizen Sells 15,000 Shares of Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Merck & Co., Inc. (NYSE:MRK) CFO Caroline Litchfield Sells 41,997 Shares - MarketBeat
Merck And Company Inc (NYSE:MRK) Healthcare Momentum In S&P 500 Today - Kalkine Media
Merck & Co., Inc. (NYSE:MRK) Shares Up 1.8% Following Analyst Upgrade - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $140.00 - MarketBeat
Willis Investment Counsel Raises Stake in Merck & Co., Inc. $MRK - MarketBeat
Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating - marketscreener.com
Merck & Co., Inc. $MRK Holdings Cut by Fishman Jay A Ltd. MI - MarketBeat
Bessemer Group Inc. Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.1% on Analyst Upgrade - MarketBeat
Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress - Finviz
Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval - TechStock²
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - Reuters
Savant Capital LLC Boosts Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Triglav Investments D.O.O. - MarketBeat
Envestnet Asset Management Inc. Decreases Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
ABN AMRO Bank N.V. Acquires 37,932 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Holdings Lowered by Homestead Advisers Corp - MarketBeat
Merck & Co., Inc. $MRK Position Increased by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg
Merck & Co., Inc. (NYSE:MRK) Trading 2.2% Higher Following Earnings Beat - MarketBeat
Where is Merck & Co. (MRK) headed according to Wall Street? - MSN
Jim Cramer on Merck & Co.: “This is one of my favorite pharmaceutical stocks” - MSN
Jim Cramer on Merck & Co.: "This Is One of My Favorite Pharmaceutical Stocks" - Finviz
Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $120.00 at Citigroup - MarketBeat
Merck & Co Inc (NYSE:MRK) Tops Estimates - FXDailyReport.Com
Looking Into Merck & Co Inc's Recent Short Interest - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Wells Fargo & Company Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Ashton Thomas Private Wealth LLC Acquires 43,047 Shares of Merck & Co., Inc. $MRK - MarketBeat
Citigroup Adjusts Price Target on Merck & Co to $120 From $115, Maintains Neutral Rating - marketscreener.com
Payne Capital LLC Purchases Shares of 10,540 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. Q4 Earnings Call Highlights - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Trading Up 2.2% on Earnings Beat - MarketBeat
Merck Looks Ahead To Phase III-Rich Period As Keytruda Winds Down - Citeline News & Insights
Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Gr - GuruFocus
AI for investors - MLQ.ai
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline - BioSpace
Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow - Benzinga
Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Merck shares dip as 2026 outlook misses Wall Street expectations - Proactive financial news
Merck’s Forecast Misses Expectations on Gardasil Woes - Bloomberg.com
Merck & Co., Inc. (NYSE:MRK) Issues FY 2026 Earnings Guidance - MarketBeat
Merck & Co., Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Merck beats on fourth quarter revenue but disappoints on outlook - Sharecast.com
Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors - Chartmill
Jim Cramer on Merck & Co.: "I Think It Can Spread Out the Wealth" - Finviz
Jim Cramer on Merck & Co.: “I Think It Can Spread Out the Wealth” - Yahoo Finance
Merck stock dips as 2026 outlook falls short of expectations (MRK:NYSE) - Seeking Alpha
Our Q4 and full-year 2025 financial results - Merck.com
Merck & Co., Inc. 8-K Filing Analysis - TradingView
Merck & Co., Inc. $MRK Shares Sold by Jones Financial Companies Lllp - MarketBeat
Merck's Q4 sales rise by 5% to $16.4B - breakingthenews.net
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - Business Wire
Where is Merck & Co. (MRK) Headed According to Wall Street? - Finviz
3.14%
자본화:
|
볼륨(24시간):